Supernus Pharmaceuticals, Inc.



$37.25Share Price
$2.0 BMarket Cap
4.5%EBIT / EV
5.3%FCF / EV
126.5%Cash ROIC
327.5%3yr Avg Revenue Growth
1.82Current Ratio
star logo

Business Model Diligence

We do not yet have Business Model Diligence for this stock.

Statistical Diligence

gray wandCurrent member of one or more spells! Log in to see which ones.
x mark The EBIT / Enterprise Value of 4.5% ranks as Below Average.
check mark The Free Cash Flow / Enterprise Value of 5.3% ranks as Above Average.
check mark The Return on Invested Capital Value of 107.3% ranks as Very High.
check mark The Cash Return on Capital Value of 126.5% ranks as Very High.
check mark The 3 Year Average Revenue Growth Value of 327.5% ranks as Very High.
check mark Near-term Financial Health appears to be Very Good. The Current Ratio is 1.82.

Company Description

Supernus Pharmaceuticals, Inc. engages in the development and commercialization of products for the treatment of central nervous system diseases. Its neurology portfolio consists of Oxtellar XR and Trokendi, which treats patients with epilepsy. It also develops product candidates for the treatment of impulsive aggression and for the treatment of attention deficit hyperactivity disorder. The company was founded by Jack A. Khattar on March 30, 2005 and is headquartered in Rockville, MD.


You must have a MagicDiligence Membership to view the Calculations for this stock. If you are already a member, you need to log in first.
Tracking Portfolios
blue wand Magic Recipe 33.56%
purple wand Deep Value 26.96%
orange wand Quality Growth 54.79%
green wand Green Team 16.01%
red dot Red Rating 8.00%
yellow dot Yellow Rating 20.92%
green dot Green Rating 28.22%
New Spell Stocks
blue wand Ubiquiti Networks, Inc. (UBNT)
blue wand Cambrex Corporation (CBM)
purple wand New Stocks Added!
orange wand New Stocks Added!